555 related articles for article (PubMed ID: 18024053)
1. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Ernst EJ; Hollanbaugh JL; Miller JG; Pfaller MA; Diekema DJ
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):273-7. PubMed ID: 18024053
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
3. Time to positive culture and identification for Candida blood stream infections.
Fernandez J; Erstad BL; Petty W; Nix DE
Diagn Microbiol Infect Dis; 2009 Aug; 64(4):402-7. PubMed ID: 19446982
[TBL] [Abstract][Full Text] [Related]
4. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
5. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata.
Blot S; Vandewoude K; Hoste E; Poelaert J; Colardyn F
J Hosp Infect; 2001 Apr; 47(4):308-13. PubMed ID: 11289775
[TBL] [Abstract][Full Text] [Related]
6. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
7. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
8. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007.
Nace HL; Horn D; Neofytos D
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):289-94. PubMed ID: 19376670
[TBL] [Abstract][Full Text] [Related]
10. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
Cohen Y; Karoubi P; Adrie C; Gauzit R; Marsepoil T; Zarka D; Clec'h C
Crit Care Med; 2010 Mar; 38(3):826-30. PubMed ID: 20042858
[TBL] [Abstract][Full Text] [Related]
11. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy.
Buckler BS; Sams RN; Goei VL; Krishnan KR; Bemis MJ; Parker DP; Murray DL
Pediatr Infect Dis J; 2008 Aug; 27(8):762-4. PubMed ID: 18664989
[TBL] [Abstract][Full Text] [Related]
12. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
13. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001].
Mujica MT; Finquelievich JL; Jewtuchowicz V; Iovannitti CA
Rev Argent Microbiol; 2004; 36(3):107-12. PubMed ID: 15559191
[TBL] [Abstract][Full Text] [Related]
15. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
16. The predictors of outcome in immunocompetent patients with hematogenous candidiasis.
Safdar A; Bannister TW; Safdar Z
Int J Infect Dis; 2004 May; 8(3):180-6. PubMed ID: 15109594
[TBL] [Abstract][Full Text] [Related]
17. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.
Wisplinghoff H; Seifert H; Wenzel RP; Edmond MB
Clin Microbiol Infect; 2006 Feb; 12(2):170-7. PubMed ID: 16441456
[TBL] [Abstract][Full Text] [Related]
19. [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004].
Eloy O; Blanc V; Pina P; Gaudart A; Bressolle ML; Plainvert C; Decousser JW; Pangon B; Allouch PY;
Pathol Biol (Paris); 2006; 54(8-9):523-30. PubMed ID: 17029814
[TBL] [Abstract][Full Text] [Related]
20. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
